D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer
Xing Yi Woo,B. K. Srivastava,Philip C. Mack,Joel H. Graber,Brian J. Sanderson,Michael Lloyd,Mandy Chen,Sergii Domanskyi,Regina F Gandour-Edwards,Rebekah Tsai,James L. Keck,Mingshan Cheng,Margaret Bundy,Emily L. Jocoy,Jonathan W. Riess,W. S. Holland,Stephen C. Grubb,James G. Peterson,Grace A. Stafford,Carolyn Paisie,Steven B. Neuhauser,R. Krishna Murthy Karuturi,Joshy George,Allen K. Simons,Margaret Chavaree,Clifford G. Tepper,Neal Goodwin,Susan D. Airhart,Primo N. Lara,Thomas H. Openshaw,Edison T. Liu,David R. Gandara,Carol J. Bult +32 more
TL;DR: A repository of 79 genomically and clinically annotated lung cancer PDXs available from The Jackson Laboratory that have been extensively characterized for histopathological features, mutational profiles, gene expression, and copy number aberrations are described.
Journal Article
Multimodality therapy for stage III NSCLC: Controversies, advances, and evolving approaches
TL;DR: Although the evolution of multimodality therapy in recent years has improved the outlook for patients with locally advanced NSCLC, at present only a minority achieve longterm survival and further advances will depend on carefully planned and conducted clinical research studies.
Journal ArticleDOI
Phase I and correlative science trial of UCN-01 plus cisplatin (CDDP) in advanced solid tumors: A California Cancer Consortium study
P. C. Mack,P. N. Lara,Jeffrey Longmate,Paul H. Gumerlock,Timothy W. Synold,James H. Doroshow,David R. Gandara +6 more
TL;DR: Findings from the correlative science and PK studies and the final clinical results of the phase I trial are consistent with predicted cell cycle regulatory effects of UCN-01 in modulating the molecular target (Chk1).
Journal ArticleDOI
Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study.
John Sarantopoulos,Antje Hoering,Timothy W. Synold,Devalingam Mahalingam,Ding Wang,Heinz-Josef Lenz,P. O'Rourke,Rachel Sexton,Peter J. Van Veldhuizen,Monica M. Mita,Lucas Wong,Alain C. Mita,Anthony B. El-Khoueiry,Vincent Chung,David R. Gandara,Sheela Tejwani,Naoko Takebe,Chris H. Takimoto,S. Percy Ivy,Razelle Kurzrock +19 more
TL;DR: A phase I study to determine maximum tolerated dose (MTD) and pharmacokinetics (PK) of D in patients (pts) with liver dysfunction (LD) and to collect data for NCI ODWG Organ Dysfunction Working GroupCriteria.